We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NOX-E36 bietet vielversprechende Entwicklungsmöglichkeiten für Augenkrankheiten mit einem hohen Bedarf an gut verträglichen Therapien mit antifibrotischer Wirkung Die antifibrotische...
NOX-E36 presents promising opportunity for development in eye diseases with a high need for well-tolerated therapies with anti-fibrotic effect Anti-fibrotic mode of action of NOX-E36 was...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0066 | 4.73457675753 | 0.1394 | 0.18 | 0.126 | 1001690 | 0.15807168 | DE |
4 | 0.021 | 16.8 | 0.125 | 0.18 | 0.1124 | 402820 | 0.14854925 | DE |
12 | -0.0016 | -1.08401084011 | 0.1476 | 0.18 | 0.1124 | 432428 | 0.14661694 | DE |
26 | -0.104 | -41.6 | 0.25 | 0.26 | 0.1124 | 356086 | 0.15962631 | DE |
52 | -0.244 | -62.5641025641 | 0.39 | 0.47 | 0.1124 | 612600 | 0.25196585 | DE |
156 | 0.1042 | 249.282296651 | 0.0418 | 5.98 | 0.0398 | 317908 | 0.35703849 | DE |
260 | 0.1042 | 249.282296651 | 0.0418 | 5.98 | 0.0398 | 317908 | 0.35703849 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions